

POST-MARKET REVIEW OF AUTHORITY REQUIRED PBS LISTINGS

Private Submission regarding PBS Listing for Remicade (Infliximab)

As the burden of Inflammatory bowel disease is increasing in incidence and severity so is the utilisation of medication such as Remicade. The number of children and adults attending hospitals and infusion centres to be assessed and receive medication has increased exponentially as has the complexity of the administration around both initiation and maintenance of this medication. The completion of forms now takes up a considerable amount of clinic time which is increasingly scarce because of the increasing number of patient consultations required.

I write in strong support of any measures that lead to a simpler administrative access to Remicade including streamlined authority codes and/or telephone authority.